<DOC>
	<DOC>NCT00303186</DOC>
	<brief_summary>The purpose of this study is to conduct an economic analysis on the cost of conventional therapy as compared to biologic therapy and the direct/indirect costs of disease management in patients with refractory psoriatic arthritis (PsA). Primary outcomes are to qualify the economic burden of refractory PsA care. The secondary outcomes are to assess efficacy, safety, and cost effectiveness of different therapies.</brief_summary>
	<brief_title>Study Evaluating the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<criteria>Eighteen years of age or older Inflammatory arthropathy associated with psoriasis meet the ACR criteria for PsA Patients with diagnosis of active and progressive PsA who have failure with conventional treatments Significant concurrent medical diseases including cancer or a history of cancer, uncontrolled congestive heart failure, myocardial infarctions within 12 months or other clinically significant cardiovascular diseases, immunodeficiency syndromes or concomitant infectious diseases.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>